Literature DB >> 22733539

Role of hedgehog signaling in malignant pleural mesothelioma.

Yandong Shi1, Ubiratan Moura, Isabelle Opitz, Alex Soltermann, Hubert Rehrauer, Svenja Thies, Walter Weder, Rolf A Stahel, Emanuela Felley-Bosco.   

Abstract

PURPOSE: The aim of this study was to assess the activity of hedgehog signaling pathway in malignant pleural mesothelioma (MPM). EXPERIMENTAL
DESIGN: The expression of hedgehog signaling components was assessed by quantitative PCR and in situ hybridization in 45 clinical samples. Primary MPM cultures were developed in serum-free condition in 3% oxygen and were used to investigate the effects of smoothened (SMO) inhibitors or GLI1 silencing on cell growth and hedgehog signaling. In vivo effects of SMO antagonists were determined in an MPM xenograft growing in nude mice.
RESULTS: A significant increase in GLI1, sonic hedgehog, and human hedgehog interacting protein gene expression was observed in MPM tumors compared with nontumoral pleural tissue. SMO antagonists inhibited GLI1 expression and cell growth in sensitive primary cultures. This effect was mimicked by GLI1 silencing. Reduced survivin and YAP protein levels were also observed. Survivin protein levels were rescued by overexpression of GLI1 or constitutively active YAP1. Treatment of tumor-bearing mice with the SMO inhibitor HhAntag led to a significant inhibition of tumor growth in vivo accompanied by decreased Ki-67 and nuclear YAP immunostaining and a significant difference in selected gene expression profile in tumors.
CONCLUSIONS: An aberrant hedgehog signaling is present in MPM, and inhibition of hedgehog signaling decreases tumor growth indicating potential new therapeutic approach. ©2012 AACR.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22733539     DOI: 10.1158/1078-0432.CCR-12-0599

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  33 in total

Review 1.  Hippo/YAP pathway for targeted therapy.

Authors:  Emanuela Felley-Bosco; Rolf Stahel
Journal:  Transl Lung Cancer Res       Date:  2014-04

2.  Combined treatment with inhibitors of ErbB Receptors and Hh signaling pathways is more effective than single treatment in reducing the growth of malignant mesothelioma both in vitro and in vivo.

Authors:  Roberto Bei; Monica Benvenuto; Chiara Focaccetti; Sara Fazi; Marta Moretti; Daniela Nardozi; Valentina Angiolini; Sara Ciuffa; Loredana Cifaldi; Raffaele Carrano; Camilla Palumbo; Martino Tony Miele; Riccardo Bei; Giovanni Barillari; Vittorio Manzari; Enrico De Smaele; Andrea Modesti; Laura Masuelli
Journal:  J Transl Med       Date:  2022-06-25       Impact factor: 8.440

Review 3.  Misactivation of Hedgehog signaling causes inherited and sporadic cancers.

Authors:  David R Raleigh; Jeremy F Reiter
Journal:  J Clin Invest       Date:  2019-02-01       Impact factor: 14.808

Review 4.  Latest developments in our understanding of the pathogenesis of mesothelioma and the design of targeted therapies.

Authors:  Angela Bononi; Andrea Napolitano; Harvey I Pass; Haining Yang; Michele Carbone
Journal:  Expert Rev Respir Med       Date:  2015-08-26       Impact factor: 3.772

Review 5.  "Hedgehog pathway": a potential target of itraconazole in the treatment of cancer.

Authors:  Xin Wei; Wu Liu; Jia Qi Wang; Zeyao Tang
Journal:  J Cancer Res Clin Oncol       Date:  2020-01-20       Impact factor: 4.553

Review 6.  Biomolecular and clinical practice in malignant pleural mesothelioma and lung cancer: what thoracic surgeons should know.

Authors:  Isabelle Opitz; Raphael Bueno; Eric Lim; Harvey Pass; Ugo Pastorino; Mattia Boeri; Gaetano Rocco
Journal:  Eur J Cardiothorac Surg       Date:  2014-03-12       Impact factor: 4.191

7.  Mutational analysis of hedgehog signaling pathway genes in human malignant mesothelioma.

Authors:  Chuan Bian Lim; Cecilia M Prêle; Hui Min Cheah; Yuen Yee Cheng; Sonja Klebe; Glen Reid; D Neil Watkins; Svetlana Baltic; Philip J Thompson; Steven E Mutsaers
Journal:  PLoS One       Date:  2013-06-24       Impact factor: 3.240

8.  SMO expression level correlates with overall survival in patients with malignant pleural mesothelioma.

Authors:  Yi Zhang; Jianxing He; Fang Zhang; Hui Li; Dongsheng Yue; Changli Wang; David M Jablons; Biao He; Natalie Lui
Journal:  J Exp Clin Cancer Res       Date:  2013-02-05

9.  Expression of the glioma-associated oncogene homolog 1 (gli1) in advanced serous ovarian cancer is associated with unfavorable overall survival.

Authors:  Alessandra Ciucci; Ilaria De Stefano; Valerio Gaetano Vellone; Lucia Lisi; Carolina Bottoni; Giovanni Scambia; Gian Franco Zannoni; Daniela Gallo
Journal:  PLoS One       Date:  2013-03-28       Impact factor: 3.240

10.  Gli as a novel therapeutic target in malignant pleural mesothelioma.

Authors:  Hui Li; Natalie Lui; Tiffany Cheng; Hsin-Hui K Tseng; Dongsheng Yue; Etienne Giroux-Leprieur; Hanh T Do; Qing Sheng; Joy Q Jin; Thomas W Luh; David M Jablons; Biao He
Journal:  PLoS One       Date:  2013-03-06       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.